glp-1 receptor agonist blue cross blue shield to stop covering popular weight-loss drugs glp-1 receptor agonist blue cross
Description
Most people experience some weight regain after stopping GLP-1 medications, as hunger hormones return to pre-treatment levels
Interestingly, higher incidence of diabetic retinopathy (DR) complications was noted in patients taking semaglutide (3.0%) compared to placebo (1.5%) in clinical trials, with greater risk in those with a history of DR [32]
Diabetes 63 , 12241233 (2014)
Implications Type 2 diabetes mellitus (T2DM): In T2DM, responsiveness to GIP is often impaired
Discovery The development of GLP-1 based drugs for obesity did not happen overnight
[Accessed on 23.11.2014]
